The position of recently developed broad-spectrum cephem antibiotics in bacterial septicemia.
In-vitro studies with cefpirome or cefepime prove that both agents are highly active against Gram-negative bacilli and Gram-positive cocci. They possess a broader spectrum of activity than ceftazidime. In clinical trials cefpirome at doses ranging from 1 g to 2 g b.i.d. was compared to ceftazidime at a dose ranging from 1 g to 2 g b.i.d. or 2 g t.i.d. Cefepime at a dose of 2 g b.i.d. was compared to ceftazidime at a dose of 2 g t.i.d. Both cefpirome and cefepime were found to be as effective as ceftazidime in patients with septicemia. These new compounds are a valuable addition to the range of drugs available for empiric treatment of serious bacterial infections.
Shah
P M
PM
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany.
D016470:Bacteremia / Q000188:drug therapy* / Q000209:etiology; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D000077723:Cefepime; D002511:Cephalosporins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D000097572:Cefpirome
D000077723:Cefepime; D002511:Cephalosporins; D000097572:Cefpirome